Edwards Lifesciences Corporation (NYSE:EW) Insider Sells $698,637.00 in Stock

Key Points

• Insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences for a total of $698,637, representing a 4.15% decrease in his position, while still holding 206,900 shares valued at around $16.15 million.
• Edwards Lifesciences recently reported earnings of $0.67 per share, beating expectations and showing an 11.9% increase in revenue year-over-year, amounting to $1.53 billion.
• Several analysts upgraded their ratings on EDW stock, with target prices ranging from $85 to $95, indicating a general optimism around the company's performance.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Stock Up 0.0%

EW traded up $0.04 during trading on Monday, hitting $78.30. The stock had a trading volume of 4,287,704 shares, compared to its average volume of 4,503,944. The company has a market capitalization of $45.97 billion, a PE ratio of 11.27, a PEG ratio of 3.78 and a beta of 1.08. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a 50 day simple moving average of $77.13 and a two-hundred day simple moving average of $74.42.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm earned $0.70 earnings per share. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $49,038,000. Dynamic Advisor Solutions LLC raised its holdings in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the last quarter. Finally, Advanced Portfolio Management LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $328,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

EW has been the subject of several recent research reports. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Finally, Barclays boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 25th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.